Last reviewed · How we verify
NCT03710057
Effect of Ivabradine in Lowering Heart Rate and Quality of Life in Chronic Heart Failure Patients
trial testing Ivabradine in Chronic Heart Failure in 50 participants. Completed in 15 May 2017.
14 February 2017
Quick facts
| Lead sponsor | Getz Pharma |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 50 |
| Start date | 1 December 2016 |
| Primary completion | 14 February 2017 |
| Estimated completion | 15 May 2017 |
Drugs / interventions tested
- Ivabradine (IVABRADINE) — full drug profile →
Conditions studied
- Chronic Heart Failure — all drugs for Chronic Heart Failure →
Sponsor
Getz Pharma — full company profile →
Who can join
Adults 30 to 70, any sex, with Chronic Heart Failure. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Elevated Heart rate (HR) (≥ 70 bpm) is one of the contributing factors in increasing the burden of hospitalization among Heart Failure patient. Ivabradine is a novel, selective and specific in inhibiting a Funny current in sinoatrial node Node and approved as an alternative therapy for Chronic Heart Failure (CHF) patients. CHF patients when treated with Ivabradine reported 39%, and 30% reduction in mortality and hospitalization rate respectively. Patient were treated with Ivabradine 5mg twice daily to determine its effect in lowering Heart rate and the Quality of Life (QOL) in Chronic Heart Failure patients
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03710057
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Ivabradine
Trials testing the same drug.
- NCT07268170 — Heart Rate Control Before Cardiac Computed Tomography in Adults for the Evaluation of Coronary Artery Disease · Phase 2, PHASE3 · enrolling by invitation
- NCT06312891 — Value of Heart Rate Lowering Therapy in Acute Myocarditis · unknown
- NCT06305806 — RECOVER-AUTONOMIC: Platform Protocol, Appendix B (Ivabradine) · Phase 2 · completed
- NCT06670690 — Comparison Between Atenolol,Propnalol and Ivabradine · NA · completed
- NCT05481177 — Ivabradine for Long-Term Effects of COVID-19 With POTS Cohort · Phase 4 · unknown
Other recruiting trials for Chronic Heart Failure
Currently open trials in the same condition.
- NCT07265349 — A Phase I/II Clinical Trial of Intramyocardial Injection of HucMSCs for the Treatment of Chronic Heart Failure · Phase 1, PHASE2 · recruiting
- NCT07379840 — A Study to Learn More About How Safe Finerenone is and How Well it Works in Adults With Chronic Heart Failure in South K · recruiting
- NCT07325942 — Effectiveness of Low -Versus High -Volume High -Intensity Interval Training in Patients With Chronic Heart Failure · NA · recruiting
- NCT07434193 — Biventricular or Left Bundle Branch Pacing to Assess the Effect of Cardiac Resynchronization Therapy in Patients Undergo · NA · recruiting
- NCT07405944 — Vericiguat and Reverse Remodeling Indices in Heart Failure · Phase 4 · recruiting
Other Getz Pharma trials
Trials by the same sponsor.
- NCT07174297 — Acotiamide vs Itopride in Postprandial Distress Syndrome · Phase 3 · not yet recruiting
- NCT07031141 — Diabetes Foot Africa Region Registry · not yet recruiting
- NCT06706609 — Classification of Adult-onset Diabetes in Five Subgroups in Pakistani Population · not yet recruiting
- NCT05977647 — Medical Stone Expulsive Therapy for Acutely Obstructed Ureteric Calculi · Phase 4 · completed
- NCT05644717 — Effect of Erugliflozin On Liver Fat, Liver Fibrosis and Glycemic Control in Type II DM Patients With NASH/NAFLD · Phase 4 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03710057 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Getz Pharma
- Last refreshed: 17 October 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03710057.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing